DEVICE SOFTWARE QUALITY AUDIT PROCEDURES SHOULD BE DEVELOPED THROUGH FDA/INDUSTRY MEETINGS, FDA SAYS; CLASSIFICATION TO TAKE MORE THAN TWO YEARS
This article was originally published in The Gray Sheet
Executive Summary
Medical device software quality audit procedures merit further development at workshops over the next year by FDA, manufacturer, and information technology representatives, Harvey Rudolph, deputy director of the Office of Science and Technology in FDA's Center for Devices and Radiological Health, said at a Sept. 3-4 FDA software policy workshop in Bethesda, Maryland.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.